'Going Viral' is the first in a new series of audio podcasts. This episode, featuring Dr Sandy Douglas from the Jenner Institute, explores how we learn to use viruses to our own advantage, in fighting them with vaccines as well as harnessing them for use in understanding how the brain is connected.
The University of Oxford ranks Number 1 in the latest Times Higher Education (THE) World University Rankings. Oxford becomes the first British university ever to occupy top position in the global table, which judges the performance of 980 universities across 79 countries.
The University of Oxford's Professor Sir Peter Ratcliffe has won the Albert Lasker Basic Medical Research Award, one of the most prestigious prizes in medicine, for his work understanding the mechanisms by which cells sense and signal hypoxia (low oxygen levels). Hypoxia is an important component of many human diseases including cancer, heart disease, stroke, vascular disease, and anaemia.
From pre-clinical testing to field trials - development and manufacture of vaccines, immunogenicity and vaccine testing in Phases I to IV .21-25 Nov: Human and Veterinary Vaccinology
5 day Master's level course providing an overview of all aspects of human and veterinary vaccinology - from Edward Jenner to modern day vaccines.
While HIV is no longer the death sentence it once was, we are yet to defeat it entirely. However, a new study from Oxford University offers hope that HIV will eventually have nowhere to hide. Tom Calver spoke to Professor Lucy Dorrell (Jenner Investigator) about her work on clearing HIV from the body.
CONACyT will fund through its 2016 “Frontiers of Science” call a project submitted by Dr Héctor Vivanco Cid of Universidad Veracruzana in collaboration with Prof Reyes-Sandoval Group, The Jenner Institute, Nuffield Department of Medicine. The study will take place in in the sate of Veracruz, which has had the highest numbers of cases of dengue fever and dengue haemorrhagic fever in Mexico in recent years, and the highest number of hospitalisations due to this disease. It is expected that chikungunya and zika viruses will become endemic in this region as well.
(CNN) As director of the Jenner Institute, Hill is creating a well-crafted "potion" of ingredients which, when combined inside a vaccine, could prepare our immune system to attack biological invaders. His formulation could one day form the foundation to protect humans from a range of diseases including malaria, HIV and tuberculosis. It's being harnessed to design a new class of vaccine, unlike any other in use today, with an end goal of disease elimination. "This is being assessed widely for use in cancer, Hepatitis C, and we've used it in Ebola and HIV," says Hill. "There are 8 different diseases where [this] approach is in clinical trial."
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children. Dr Anna Rautanen from Adrian Hill's research group at the Wellcome Trust Centre for Human Genetics, said: 'Critically, the genetic variants we have identified carry a doubled risk of developing bacteraemia when infected with the Streptococcus pneumoniae bacteria. This discovery therefore provides clues in the pressing search for new ways to target the disease.'
Red tape is hampering scientists from developing groundbreaking GM vaccines, it is claimed. Adrian Hill, of Oxford University, said that this was holding back research. “Because the vaccine is technically a GM organism, if we’re going to vaccinate someone in our clinic we need special permission, not to protect the person from the dangers of the vaccine but to protect from the potential risks of that microbe getting out and contaminating the environment,” he said. This was despite the fact, he added, that it would not survive.
Oxford spin out company Vaccitech has launched today with £10m seed investment to develop a universal flu vaccine already showing promise in clinical trials. Vaccitech has raised £10m from investment company Oxford Sciences Innovation to take a number of vaccines through clinical trials. Vaccitech’s lead product is a “universal” flu vaccine which would work against all varieties of the virus. “We’ve targeted two proteins inside the virus which do not change, even as the virus mutates the proteins on its surface,” explains Adrian Hill, director of the Jenner Institute. Vaccitech is also working on vaccines to fight cancer by turning the immune system against the disease.
The Financial Times: Oxford biotech deals highlight stature of UK university spinouts.
If you have news or events that you would like to be added to this website, please email us details. If possible, please include a picture and links to further information.